読み込み中
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
前日終値
$0.89
−$0.0549 · -5.81%
日中の時刻はETです。市場データは遅延する場合があります。
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
日中レンジ
現在 $0.89
52週レンジ
現在 $0.89
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
42
適正価値
センチメント
51
まちまち
リスク
69
高リスク
モメンタム
37
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
日中レンジ
現在 $0.89
52週レンジ
現在 $0.89
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（SGD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 31.92万 SGD | 6.95万 SGD | 50.91万 SGD | 36.56万 SGD | — |
| 売上原価 | 120.58万 SGD | 1.71万 SGD | 3736 SGD | 10.9万 SGD | 3501 SGD |
| 粗利益 | −88.66万 SGD | 5.24万 SGD | 50.54万 SGD | −10.9万 SGD | 11.03万 SGD |
| 研究開発 | 218.21万 SGD | 190.95万 SGD | 159.4万 SGD | 152.22万 SGD | 109.02万 SGD |
| 販売・一般管理 | 144.18万 SGD | 126.57万 SGD | 49.05万 SGD | 59.65万 SGD | 58.85万 SGD |
| 営業費用 | 363.32万 SGD | 318.29万 SGD | 208.45万 SGD | 217.42万 SGD | 126.69万 SGD |
| 受取利息 | 12.19万 SGD | 31.77万 SGD | 28.15万 SGD | 2046 SGD | 3389 SGD |
| 支払利息 | 2.06万 SGD | 2.03万 SGD | 5.05万 SGD | 12.21万 SGD | 11.84万 SGD |
| 減価償却費と償却費 | 40.16万 SGD | 33.54万 SGD | 38.11万 SGD | 39.29万 SGD | 32.99万 SGD |
| 営業利益 | −451.98万 SGD | −313.05万 SGD | −157.92万 SGD | −228.32万 SGD | −115.63万 SGD |
| 純利益 | −391.68万 SGD | −251.67万 SGD | −414.42万 SGD | −305.55万 SGD | −207.37万 SGD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
